🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#SABCS24 P2-06-13 | Dr. Dennis Sgroi Mass General Brigham Pathology showed how HOXB13 expression induces an immunosuppressive TME in #breastcancer using ER+ SSM3-HOXB13 & ER- PyMT-HOXB13 mouse mammary tumor cells: 📈 Increased tumor growth rate 📉 Decreased CD3+ & CD8+ T cell infiltration

#SABCS24 P2-09-21 | Dr. Seth Wander Mass General Cancer Center presented low-level Aurora kinase A amplification as a novel personalized biomarker of CDK4/6i resistance in patients with HR+ metastatic #breastcancer ⬇️

#SABCS24 P3-05-16 | Tess O'Meara, MD, MHS presented a case series of 7 patients with extreme ESR1 polyclonality to showcase the biologic importance of this in ER+ metastatic #BreastCancer Key Topics: 📊 Frequency of ESR1 and associated clones 🔍 Mutation dynamics 📊 Co-mutation patterns

#SABCS24 P3-05-18 | Dr. Dejan Juric presented on the prognostic value of ctDNA dynamics & protein biomarkers in patients treated with alpelisib & endocrine therapy for HR+/HER2- PIK3CA-mutated advanced #breastcancer in all 3 cohorts of the phase II BYLieve study ⬇️

🗓️ Today 7PM CT | Clinical Care Options CME-certified symposium bit.ly/4f7JlVh | #SABCS24 Dr. Laura Spring will join VIRGINIA KAKLAMANI & Erica Mayer to discuss ER mutations in HR+ advanced #breastcancer, including mutation screening to guide therapeutic decision-making with SERDs

#SABCS24 P3-10-10 | Dr. Rachel Abelman Mass General Cancer Center presented a retrospective analysis of PIK3CA and AKT inhibitors in HR+, HER2- metastatic #breastcancer ⬇️

#SABCS24 P3-04-06 | Dr. Zuen Ren Mass General Cancer Center presented his work on BRCA1/2 genetic carriers: 🔍 Exploring genomic & transcriptomic changes using simultaneous scWGS & scRNAseq of LPs 🔬 Elucidating the mechanistic link between BRCA1/2 mutations & progenitor cell fates

🗓️ Today, 12/13 12:30PM CT | Poster Session 5 | Halls 2-3 | #SABCS24 🚨 #SABCS24 Day 4 is here! Don't miss Dr. Neelima Vidula's poster on best response to SG and T-DXd based on organ site of metastatic #breastcancer treatment - stop by and learn more!

🗓️ Thurs, Dec 19 4:30PM ET | MASCC webinar Amy Comander MD, DipABLM will join Maryam Lustberg MD, MPH, FASCO and Roberta A Albany to discuss managing menopause after #breastcancer. 🔑 Key topics: weight gain and hot flashes 👉 Register here: us02web.zoom.us/webinar/regist…

🗓️ Sat, Dec 21 9AM ET | sisbreastlive.com Join Tolga OZMEN, MD Mass General Surgery, Dr. Carole Mathelin, Canan Dagdeviren, Dr. Alexander Mundinger, and Dr. Darius Dian for this webinar on AI in #breastcancer! 🔑 Key topics: screening, oncoplastic surgery 👉 No registration required

This study led by Dr. Rupali Sood & Dr. Neelima Vidula evaluates clinical/genomic characteristics, trial participation, and genotype-matched therapy among patients with metastatic #breastcancer - barriers to precision oncology need addressing Clinical Cancer Research: aacrjournals.org/clincancerres/…

Building on prior work, Dr. Neelima Vidula & MGH Breast Oncology colleagues describe brain metastases in patients with metastatic #breastcancer & cfDNA somatic BRCA1/2 mutations - cfDNA may help identify patients at higher risk for developing brain metastases ⬇️ link.springer.com/article/10.100…

🎉 Congratulations to Charlie Dai Mass General Cancer Center and Maxwell Lloyd BIDMC IM Residency on receiving a Young Investigator Award during #ASCO25!

🚨 June 1 | 8AM CDT | Breast Cancer - Local/Regional/Adjuvant Don't miss Rachel Occhiogrosso Abelman, MD Mass General Cancer Center presenting results from the NeoSTAR trial, a phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab in patients with early-stage TNBC! #ASCO25

Rachel Occhiogrosso Abelman, MD, presented her phase 2 trial for patients with early stage, triple negative breast cancer at #ASCO25.

📢 Rachel Occhiogrosso Abelman, MD unveils results from the NeoSTAR trial at #ASCO25 🔑 4 cycles of pre-op SG+P resulted in a 32% pCR rate in early-stage TNBC 🔑 No new safety signals identified 🔑 50% of patients achieved pCR with a non-anthracycline regimen (SG+P only or with additional NACT)

National Cancer Survivor's Day is a day to #CelebrateLife and acknowledge the resilience, strength, and courage of those who have been affected by cancer. #NCSD2025 Pictured are some of our patient story participants.

📰 Dr. Arielle Medford led this genomic & proteomic profiling of GATA3mut in HR+ MBC -Distinct ctDNA-based genomic landscape -CPTAC analysis suggests mechanism for sensitivity to MDM2 inhibition -GATA3mut associated with poorer survival on ET monotherapy link.springer.com/article/10.100…